OBJECTIVES: This study evaluated the effect of comorbidity at diagnosis on racial differences in survival among men with prostate cancer. METHODS: Clinical and demographic data were abstracted from records of 864 patients diagnosed at 4 Chicago area hospitals between 1986 and 1990. Comorbidity was scored on the basis of clinical information in the Charlson index. Cause-specific relative mortality adjusted for age, stage, differentiation, and treatment was compared across Charlson scores with Cox proportional hazards functions. RESULTS: Blacks had significantly greater mortality from prostate cancer and other causes (vs Whites, relative risk [95% confidence interval] = 1.84 [1.22, 2.79] and 1.69 [1.33, 2.29], respectively; P <.001). However, differences disappeared as initial comorbidity increased (1.75 [1.33, 2.31] vs 0.90 [0.59, 1.29] for scores = 0 and > or =5, respectively). CONCLUSIONS: Absence of a significant preexisting medical diagnosis is associated with a higher risk for excess mortality among Black men diagnosed with prostate cancer.
OBJECTIVES: This study evaluated the effect of comorbidity at diagnosis on racial differences in survival among men with prostate cancer. METHODS: Clinical and demographic data were abstracted from records of 864 patients diagnosed at 4 Chicago area hospitals between 1986 and 1990. Comorbidity was scored on the basis of clinical information in the Charlson index. Cause-specific relative mortality adjusted for age, stage, differentiation, and treatment was compared across Charlson scores with Cox proportional hazards functions. RESULTS: Blacks had significantly greater mortality from prostate cancer and other causes (vs Whites, relative risk [95% confidence interval] = 1.84 [1.22, 2.79] and 1.69 [1.33, 2.29], respectively; P <.001). However, differences disappeared as initial comorbidity increased (1.75 [1.33, 2.31] vs 0.90 [0.59, 1.29] for scores = 0 and > or =5, respectively). CONCLUSIONS: Absence of a significant preexisting medical diagnosis is associated with a higher risk for excess mortality among Black men diagnosed with prostate cancer.
Authors: N M Makridakis; R K Ross; M C Pike; L E Crocitto; L N Kolonel; C L Pearce; B E Henderson; J K Reichardt Journal: Lancet Date: 1999-09-18 Impact factor: 79.321
Authors: Susan Halabi; Sandipan Dutta; Catherine M Tangen; Mark Rosenthal; Daniel P Petrylak; Ian M Thompson; Kim N Chi; John C Araujo; Christopher Logothetis; David I Quinn; Karim Fizazi; Michael J Morris; Mario A Eisenberger; Daniel J George; Johann S De Bono; Celestia S Higano; Ian F Tannock; Eric J Small; William Kevin Kelly Journal: J Clin Oncol Date: 2018-12-21 Impact factor: 44.544
Authors: Mark D Tyson; JoAnn Alvarez; Tatsuki Koyama; Karen E Hoffman; Matthew J Resnick; Xiao-Cheng Wu; Matthew R Cooperberg; Michael Goodman; Sheldon Greenfield; Ann S Hamilton; Mia Hashibe; Lisa E Paddock; Antoinette Stroup; Vivien W Chen; David F Penson; Daniel A Barocas Journal: Eur Urol Date: 2016-11-03 Impact factor: 20.096
Authors: Vincent L Freeman; Ana C Ricardo; Richard T Campbell; Richard E Barrett; Richard B Warnecke Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-07-22 Impact factor: 4.254
Authors: Mary Putt; Judith A Long; Chantal Montagnet; Jeffrey H Silber; Virginia W Chang; J Sanford Schwartz; Craig Evan Pollack; Yu-Ning Wong; Katrina Armstrong Journal: Med Care Res Rev Date: 2009-04-08 Impact factor: 3.929
Authors: Chen-Pin Wang; Donna M Lehman; Yui-Wing F Lam; John G Kuhn; Devalingam Mahalingam; Steven Weitman; Carlos Lorenzo; John R Downs; Elizabeth A Stuart; Javier Hernandez; Ian M Thompson; Amelie G Ramirez Journal: Cancer Prev Res (Phila) Date: 2016-03-29
Authors: S Halabi; S Dutta; C M Tangen; M Rosenthal; D P Petrylak; I M Thompson; K N Chi; J S De Bono; J C Araujo; C Logothetis; M A Eisenberger; D I Quinn; K Fizazi; M J Morris; C S Higano; I F Tannock; E J Small; W K Kelly Journal: Ann Oncol Date: 2020-04-11 Impact factor: 32.976
Authors: Vonetta L Williams; Shivanshu Awasthi; Angelina K Fink; Julio M Pow-Sang; Jong Y Park; Travis Gerke; Kosj Yamoah Journal: Cancer Med Date: 2018-03-30 Impact factor: 4.452